Literature DB >> 2879804

The effect of cyclophosphamide in vivo on the expression of lymphocyte markers, detected by monoclonal antibodies, in the rat.

E el-Sady, D Parker, J L Turk.   

Abstract

Surface markers on lymphocytes from the thymus, lymph node and spleen of the rat were examined in single cell suspensions using a panel of monoclonal antibodies. These were used particularly to investigate Pan T, TH (T-helper), TS/C (T-suppressor-cytotoxic) and Ia antigens. The expression of these markers in rats treated with a single dose of cyclophosphamide (100 mg/kg body weight) was followed for 3 weeks after treatment. Maximum changes were detected at 3 days and recovery took up to 3 weeks to near completion. Comparison was made with histological observations of the effect of CY on these organs. At 3 days, the thymus showed maximum weight loss and gross cortical depletion. This associated with significant drop in the expression of the TS/C marker on small and large lymphocytes. Regeneration of the cortex, beginning at 7 days, was associated with the presence of many large pyroninophilic cells. This was accompanied by an increase in the expression of the TS/C marker on both small and large lymphocytes. The mesenteric lymph node showed marked depletion of the B-cell areas at 3 days. There was also a significant drop in TS/C and Ia expression and a marked rise in Pan T and TH. TS/C expression recovered rapidly with a rebound at 7 days. However, the expression of Pan T and TH did not return to normal until 21 days. In the spleen there was a similar decrease in the lymphocytes populating the B-cell areas at 3 and 7 days with an increase in the expression of Pan T and TH, and a decrease in the expression of Ia.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2879804     DOI: 10.1016/0192-0561(86)90098-6

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  5 in total

1.  Maintenance treatment with interferon-gamma and low-dose cyclophosphamide for pediatric high-grade glioma.

Authors:  Johannes E A Wolff; Sabine Wagner; Christiane Reinert; Astrid Gnekow; R-D Kortmann; Joachim Kühl; Stefaan W Van Gool
Journal:  J Neurooncol       Date:  2006-04-28       Impact factor: 4.130

2.  Evidence of a role for NK cells in oxazaphosphorine-mediated tumor regression.

Authors:  T Reissmann; P Hilgard; R Voegeli; J Zeller
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

3.  Cyclophosphamide treatment antagonizes the in vitro development of Mycobacterium lepraemurium-induced suppressor cell precursors.

Authors:  D Gosselin; R Turcotte; S Lemieux
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

4.  Augmentation of host antitumor immunity by low doses of cyclophosphamide and mafosfamide in two animal tumor models.

Authors:  T Reissmann; R Voegeli; J Pohl; P Hilgard
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

5.  Alterations in dendritic cell phenotype and function associated with immunoenhancing effects of a subcutaneously administered cyclophosphamide derivative.

Authors:  J Limpens; M Van Meijer; H M Van Santen; W T Germeraad; K Hoeben-Schornagel; M Breel; R J Scheper; G Kraal
Journal:  Immunology       Date:  1991-07       Impact factor: 7.397

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.